Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 13, 2026, NDA 205934 (Docetaxel), held by Shilpa, was first approved by FDA on Dec 22, 2015, with 3 approved supplements and 0 published complete response letters.
First approved: Dec 22, 2015
Review: Standard
Supplements approved: 3
Complete response letters: 0
Approvals and New Uses
The original application and every efficacy supplement, newest first; all 4 submissions below
Date
Submission
Status
Documents
Dec 22, 2015
Original applicationNew formulation or manufacturer · Standard review
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
